Salacinol

Salacinol, compound found in Salacia reticulata, is an orally active α-glucosidase/lipase inhibitor. Salacinol inhibits enzymatic activity of intestinal maltase (IC₅₀ = 3.2 μg/mL, K_i = 0.31 μg/mL), sucrase (IC₅₀ = 0.84 μg/mL, K_i = 0.32 μg/mL), and isomaltase (IC₅₀ = 0.59 μg/mL, K_i = 0.47 μg/mL), and inhibits increases in serum glucose levels in sucrose-loaded rats. Salacinol also inhibits pancreatic lipase and lipoprotein lipase. Salacinol can be used for the research of diabetes mellitus^[1][2]. In Vitro:Salacinol (300 mg/L; 30 min) significantly inhibits porcine pancreatic lipase activity by 12.6%^[1].
Salacinol (100 mg/L; 2 h) significantly inhibits rat adipose tissue-derived lipoprotein lipase activity by 13.6%^[1].
Salacinol (100 mg/L; 18 h) reduces remaining triglyceride content in rat epididymal fat-derived adipocytes to 75.3% of vehicle control^[1].
Salacinol (30 min) competitively inhibits rat small intestinal brush border membrane vesicle maltase, sucrase, and isomaltase with IC₅₀ values of 3.2, 0.84, and 0.59 μg/mL, respectively, and K_i values of 0.31, 0.32, and 0.47 μg/mL, respectively^[2]. In Vivo:Salacinol (1.3-10 mg/kg; p.o.) potently inhibits sucrose-induced serum glucose elevation in fasted male Wistar rats, with significant activity observed at oral doses as low as 1.3 mg/kg^[2].